NEW YORK – New York is expected to receive about 164,800 doses of the Johnson & Johnson vaccine this week, pending final clearance from the FDA, Governor Andrew Cuomo said Monday, same day that the state marks one year of reporting the first case of COVID-19.
Cuomo noted that the New York State Clinical Advisory Task Force unanimously recommended the use of the COVID-19 vaccine from the pharmaceutical company Johnson & Johnson in the state, following the recommendation of the FDA advisory committee for the authorization of use. of emergency.
“A year ago today, the unimaginable tragedy of COVID-19 began for New Yorkers. We have faced great pain and loss for the past 365 days, but there is reason to be hopeful for the future, and the Advisory Task Force recommendation The state’s clinician’s upcoming COVID-19 vaccine is part of that ongoing convalescence, “Governor Cuomo said. “Johnson & Johnson’s single-dose vaccine with less restrictive storage requirements will make it easier for the state to reach more New Yorkers, faster. There is a lot of work ahead, but the approval of this vaccine gives us reason to be optimistic as we move into a post-COVID future. “
The additional doses will supplement the expected week 12 supply of 422,780 first doses and 290,500 second doses of Pfizer and Moderna, for a total of approximately 878,080 doses. This will be the highest weekly vaccine allocation in New York State history.
Johnson & Johnson’s vaccine is single-dose and there are fewer restrictions on its storage. New York State is finalizing plans for prioritization and distribution of the vaccine with partners.
On September 24, 2020, Governor Cuomo announced that New York State would form an independent Clinical Advisory Task Force comprised of leading scientists, physicians, and health experts who will review all government-authorized COVID-19 vaccines. federal. The Task Force subsequently recommended the Pfizer and Moderna vaccines.
– .
